Skip to main content
DYN
NASDAQ Life Sciences

Major Shareholder Atlas Venture Files Intent to Sell $28M in Dyne Therapeutics Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$17.47
Mkt Cap
$2.886B
52W Low
$8.06
52W High
$25
52W Position info
117% above low
Off High info
30% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

DYN has more than doubled off its 52-week low of $8.06.

Summary

Atlas Venture, a significant shareholder in Dyne Therapeutics, has filed a Form 144 indicating intent to sell an additional 6,081 shares, following recent sales totaling over $27.9 million.


Key Events · Ownership and Investor Activity · DYN

  • Proposed Share Sale

    Atlas Venture Fund XI, LP has filed a Form 144 indicating intent to sell 6,081 common shares of Dyne Therapeutics, with an approximate market value of $107,694.51.

  • Significant Recent Distribution

    This proposed sale follows a series of dispositions by Atlas Venture entities between April 20 and May 4, 2026, totaling over $27.9 million in Dyne Therapeutics common stock.

  • Institutional Investor Reducing Stake

    The cumulative sales by this major institutional shareholder represent a substantial reduction in their holdings, potentially signaling a shift in their investment outlook for the company.


Analysis · DYN · Life Sciences

This Form 144 filing by Atlas Venture, a major institutional shareholder, signals a continued distribution of its holdings in Dyne Therapeutics. The proposed sale of an additional $107,694 worth of shares comes after a series of sales by Atlas Venture entities totaling over $27.9 million in the past month. This sustained selling activity, representing nearly 1% of the company's market capitalization, could exert downward pressure on the stock price and indicates a reduction in conviction from a key early investor. Investors should monitor future filings for continued selling by this entity.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DYN was trading at $17.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DYN - Latest Insights

DYN
Nov 05, 2026, 7:25 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.63
Real-time Price: $15.50 info
Change: -$3.13 (-17%) info
Market Cap: $2.904B info
DYN
Sep 29, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.78
Real-time Price: $15.50 info
Change: -$0.280 (-2%) info
Market Cap: $2.904B info
DYN
Sep 29, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $15.50 info
Change: -$0.280 (-2%) info
Market Cap: $2.904B info
DYN
Aug 17, 2026, 5:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $26.15
Real-time Price: $15.50 info
Change: -$10.65 (-41%) info
Market Cap: $2.904B info
DYN
Aug 14, 2026, 5:47 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.94
Real-time Price: $15.50 info
Change: -$10.44 (-40%) info
Market Cap: $2.904B info